The pathomimetic oAβ 25 - 35 model of Alzheimer's disease: Potential for screening of new therapeutic agents.

Autor: Canet G; MMDN, University of Montpellier, EPHE, INSERM, Montpellier, France; Laval University, Faculty of Medicine, Department of Psychiatry and Neurosciences, CR-CHUQ, Québec City, (QC), Canada., Zussy C; MMDN, University of Montpellier, EPHE, INSERM, Montpellier, France., Hernandez C; MMDN, University of Montpellier, EPHE, INSERM, Montpellier, France., Maurice T; MMDN, University of Montpellier, EPHE, INSERM, Montpellier, France; CNRS, Paris, France., Desrumaux C; MMDN, University of Montpellier, EPHE, INSERM, Montpellier, France; LIPSTIC LabEx, Dijon, France. Electronic address: catherine.desrumaux-piazza@umontpellier.fr., Givalois L; MMDN, University of Montpellier, EPHE, INSERM, Montpellier, France; Laval University, Faculty of Medicine, Department of Psychiatry and Neurosciences, CR-CHUQ, Québec City, (QC), Canada; CNRS, Paris, France. Electronic address: laurent.givalois@umontpellier.fr.
Jazyk: angličtina
Zdroj: Pharmacology & therapeutics [Pharmacol Ther] 2023 May; Vol. 245, pp. 108398. Date of Electronic Publication: 2023 Mar 29.
DOI: 10.1016/j.pharmthera.2023.108398
Abstrakt: Alzheimer's disease (AD) is the most common form of dementia in the elderly, currently affecting more than 40 million people worldwide. The two main histopathological hallmarks of AD were identified in the 1980s: senile plaques (composed of aggregated amyloid-β (Aβ) peptides) and neurofibrillary tangles (composed of hyperphosphorylated tau protein). In the human brain, both Aβ and tau show aggregation into soluble and insoluble oligomers. Soluble oligomers of Aβ include their most predominant forms - Aβ 1 - 40 and Aβ 1 - 42 - as well as shorter peptides such as Aβ 25 - 35 or Aβ 25 - 35/40 . Most animal models of AD have been developed using transgenesis, based on identified human mutations. However, these familial forms of AD represent less than 1% of AD cases. In this context, the idea emerged in the 1990s to directly inject the Aβ 25 - 35 fragment into the rodent brain to develop an acute model of AD that could mimic the disease's sporadic forms (99% of all cases). This review aims to: (1) summarize the biological activity of Aβ 25 - 35 , focusing on its impact on the main structural and functional alterations observed in AD (cognitive deficits, APP misprocessing, tau system dysfunction, neuroinflammation, oxidative stress, cholinergic and glutamatergic alterations, HPA axis dysregulation, synaptic deficits and cell death); and (2) confirm the interest of this pathomimetic model in AD research, as it has helped identify and characterize many molecules (marketed, in clinical development, and in preclinical testing), and to the development of alternative approaches for AD prevention and therapy. Today, the Aβ 25 - 35 model appears as a first-intent choice model to rapidly screen the symptomatic or neuroprotective potencies of new compounds, chemical series, or innovative therapeutic strategies.
Competing Interests: Declaration of Competing Interest None of the authors has any conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
(Copyright © 2023 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: